ORAMED PHARMACEUTICALS INC. (ORMP) Latest Filing Signal

Latest Filing: 10-K  |  Filed Mar 26, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for ORAMED PHARMACEUTICALS INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, ORAMED PHARMACEUTICALS INC.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Positive
CHATGPT
Turned Positive

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does ORAMED PHARMACEUTICALS INC. actually do?
Answer:
Oramed Pharmaceuticals Inc. is a pharmaceutical company focused on developing an oral delivery technology platform for therapeutic proteins, notably insulin. The company's core technology aims to create an oral dosage form that can withstand the gastrointestinal tract to deliver active proteins. Oramed is advancing its oral insulin formulation through clinical trials, with a planned 60-patient US-based trial in the second half of 2026 to validate its robustness in specific patient populations. Beyond its pharmaceutical development, Oramed strategically allocates capital to investments in healthcare and life sciences companies. The company's business model is centered on innovation in drug delivery and strategic financial investments.
Question:
What are ORAMED PHARMACEUTICALS INC.'s revenue drivers?
Answer:
The company's revenue drivers are primarily from its strategic investments in healthcare and life sciences companies, and potentially from future commercialization of its oral protein delivery technology. In the past, it recognized revenue from a license agreement with HTIT.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required